×

Fulgent Genetics to Announce First Quarter 2017 Financial Results on May 8, 2017

TEMPLE CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 4012282. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 4012282 through May 15, 2017.

About Fulgent Genetics

Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com Chris Danne, 415-217-5865, chris@blueshirtgroup.com

Source:Fulgent Genetics, Inc.